American Gene Technologies® has completed our Phase 1 clinical trial and we are currently preparing to submit the final report to the FDA. In the meantime, we are designing the Phase 2 clinical trial protocol and working to identify manufacturers and trial sites. As we review the Phase 1 data with potential collaborators and partners, the response has been consistently enthusiastic to participate in the Phase 2. The analytic treatment interruption has already highlighted impressive viral suppression and immunological data for three out of the six participants who agreed to enroll from the Phase 1, and we are still collecting data on the other three participants. We can’t provide an exact date for when the final Phase 1 data will be released, as we are continuing to analyze the data. Please visit our website and sign up for our newsletter to stay informed of progress: